Discontinuation of GLP-1RA Treatment Reinstates Binge-Like Eating and Drives Body Weight Past Pre-Treatment Levels in Mice

Semaglutide reduces body weight and palatable food intake in mice with binge-like eating, but stopping treatment reinstates binge-like eating and drives body weight above pre-treatment baseline.

• Why it matters: The study addresses whether GLP-1RA benefits persist after stopping, and whether discontinuation is linked to binge-related relapse and subsequent weight regain in a binge-eating model.
• What they did: Mice in a pre-clinical binge-eating model received semaglutide, and investigators compared body weight and palatable food intake during treatment versus after discontinuation.
• The result: Discontinuation reinstated binge-like eating and led to body weight significantly exceeding pre-treatment levels, implying a specific binge-related risk after stopping GLP-1RAs in this mouse model.

AI summary of the abstract · may contain errors · not medical advice · read the paper.